Orexin/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain

Cornelia Schöne
Department of Neurology, University of Bern, Bern University Hospital, 3010 Bern, Switzerland

Denis Burdakov
The Francis Crick Institute, Mill Hill Laboratory, London NW7 1AA, UK

Abstract

An enigmatic feature of behavioural state control is the rich diversity of wake-promoting neural systems. This diversity has been rationalized as ‘robustness via redundancy’, wherein wakefulness control is not critically dependent on one type of neuron or molecule. Studies of the brain orexin/hypocretin system challenge this view by demonstrating that wakefulness control fails upon loss of this neurotransmitter system. Since orexin neurons signal arousal need, and excite other wake-promoting neurons, their actions illuminate nonredundant principles of arousal control. Here, we suggest such principles by reviewing the orexin system from a collective viewpoint of biology, physics and engineering. Orexin peptides excite other arousal-promoting neurons (noradrenaline, histamine, serotonin, acetylcholine neurons), either by activating mixed-cation conductances or by inhibiting potassium conductances. Ohm’s law predicts that these opposite conductance changes will produce opposite effects on sensitivity of neuronal excitability to current inputs, thus enabling orexin to differentially control input-output gain of its target networks. Orexin neurons also produce other transmitters, including glutamate. When orexin cells fire, glutamate-mediated downstream excitation displays temporal decay, but orexin-mediated excitation escalates, as if orexin transmission enabled arousal controllers to compute a time integral of arousal need. Since the anatomical and functional architecture of the orexin system contains negative feedback loops (e.g. orexin → histamine → noradrenaline/serotonin—orexin), such computations may stabilize wakefulness via integral feedback, a basic engineering strategy for set point control in uncertain environments. Such dynamic behavioural control requires several distinct wake-promoting modules, which perform nonredundant transformations of arousal signals and are connected in feedback loops.

Keywords

Arousal; Brain state; Control theory; Hypocretin; Hypothalamus; Neurons; Orexin

✉ denis.burdakov@crick.ac.uk.


1 Postsynaptic Actions of Orexin/Hypocretin Mediate Arousal Control

Efficient behaviour requires optimal adjustment of behavioural state (i.e. arousal, wakefulness, activity, energy expenditure) to perturbations in the environment. The environmental perturbations come in many diverse types, which differ greatly in their speed and predictability, necessitating an evolution of behavioural control systems that can deal with this perturbation diversity. A fundamental example of a slow and predictable perturbation in the environment is the ca. 24 h day-night cycle on Earth. The hypothalamic suprachiasmatic nucleus (SCN) adjusts behaviour to this cycle by emitting sinusoidal (ca. 24 h period) neural signals that schedule behavioural activity for either the day (for diurnal animals) or the night (for nocturnal animals), depending on specific survival advantages afforded to different animals by being active during light or dark. These slow daily rhythms of behavioural activity collapse upon description of the SCN [1].

However, wakefulness also needs to be controlled on a much more rapid and unpredictable timescale than that controlled by the SCN. Most of us take this rapid wakefulness adjustment for granted, assuming that we will not fall asleep in the middle of laughing or talking. This is not so for patients suffering from the sleep-wake disorder narcolepsy, which affects about 1:2000 people and where sleep and paralysis suddenly and uncontrollably intrude into normal wakefulness [2, 3]. Most cases of human narcolepsy are associated with reduced levels of orexin/hypocretin peptides in the CSF and lack of central orexin/hypocretin-producing neurons in the brain [4–7]. Loss of orexin/hypocretin peptides in humans, dogs, mice and rats impairs arousal control, resulting in abnormally frequent and rapid loss of consciousness (‘sleep attacks’). It seems that without the orexin/hypocretin system, wakefulness is prone to instability in the face of rapid perturbations in the environment, and processes enabled by orexin/hypocretin cells keep this instability under control. Orexin/hypocretin and the SCN systems are thus two hypothalamic systems that are essential for appropriate matching of behavioural state to the environment on rapid and slow timescales, respectively.

The orexin/hypocretin cells act as controllers rather than critical generators of wakefulness: with them, the average amount of arousal (sleep and waking) does not change, but the ability to control arousal based on salient environmental set point is impaired [8, 9]. Coordination of many other behaviours, such as reward-seeking, also critically relies on orexin/hypocretin neurons [10–12], but since these behaviours are wakefulness dependent, it is often unclear to what extent these effects are secondary to wakefulness control. Since the discovery of orexin/hypocretin neurons, a key question has been why they are so critical for arousal control, considering the numerous other arousal-controlling neurons in the brain (e.g. noradrenaline, histamine, acetylcholine, serotonin cells). Here, we review the biological properties of brain orexin/hypocretin circuits related to wakefulness/arousal, with particular emphasis on postsynaptic actions of orexin/hypocretin peptides and from a viewpoint of basic principles of signal processing and dynamic set point control. For more comprehensive overviews of orexin/hypocretin physiology, we refer the reader elsewhere [10, 13].

In this article, we will take the view that orexin/hypocretin neurons signal arousal need (or, in control system language, arousal error – see below). We define arousal need as a need to
counteract actual or potential dangers such as low energy levels, high CO₂ levels, or potentially threatening sensory stimuli (e.g. sudden sounds, presence of another animal). Orexin neurons sense all these signals (Fig. 1), and thus their activity represents a sum of diverse ‘arousal demands’ (e.g. they are inhibited by glucose but excited by H₂O⁻/CO₂) [8, 14–18]. Orexin/hypocretin neurons are also inhibited by at least some of the other wakefulness-promoting transmitters such as serotonin and noradrenaline, i.e. transmitters that may represent the actual level of arousal [19–21] (discussed below). Thus, orexin/hypocretin cell output may represent an ‘arousal error’ (actual arousal minus required arousal), thereby signalling how much arousal should be increased. In the absence of these orexin/hypocretin signals, arousal is no longer appropriately coupled to internal and external environment, which is an alternative way of describing sleep-wake instability.

The wake-sleep instability seen upon loss of orexin/hypocretin-producing neurons is recapitulated by the loss of orexin/hypocretin type 2 receptors or of orexin/hypocretin peptides [22–24]. This suggests that postsynaptic actions of orexin/hypocretin peptides on orexin/hypocretin type 2 G-protein-coupled receptors are responsible for arousal control mediated by orexin/hypocretin cells. This also suggests that orexin type 2 receptor-independent actions of orexin/hypocretin cells, such as those mediated by their other transmitters (glutamate, dynorphin, Narp) or by orexin/hypocretin via type 1 receptors, are insufficient to achieve proper arousal control without orexin/hypocretin action of type 2 orexin/hypocretin receptors. The latter point may seem surprising, considering that some arousal-promoting neurons, such as noradrenaline neurons of the LC which are important for orexin/hypocretin-induced wakefulness [25], are excited by orexin/hypocretin via type 1 rather than type 2 OX receptors [26]. In contrast, other arousal-promoting neurons, such as histamine cells of the tuberomammillary hypothalamus, are excited by orexin/hypocretin via type 2 receptors [26, 27]. Below, we catalogue this biological complexity of postsynaptic actions of orexin/hypocretin cells in more detail and comment on some functional biophysical implications of this complexity. Then, we propose a framework that simplifies and generalizes the diversity of postsynaptic orexin/hypocretin actions into a control systems model that accounts for general dynamic features of orexin/hypocretin-dependent arousal and offers an organizing principle for the puzzling diversity of wakefulness-promoting neurons in the brain.

2 Sites and Biophysics of Postsynaptic Actions of Orexin/Hypocretin Neurons

From their location in the lateral hypothalamus, orexin/hypocretin cells project axons to the entire brain [28, 29] (Fig. 2). The anatomical distribution of these projections largely mirrors that of two G-protein-coupled receptors for orexin [30]. Increased firing rate of orexin/hypocretin neurons produces awakening [31], and most of the brain’s classical arousal-related systems are innervated by orexin/hypocretin axons and excited by orexin/hypocretin peptides (see Table 1, which lists many key findings alongside corresponding references [19, 26, 27, 32–106]). Orexin/hypocretin peptides also modulate neuronal activity in brain areas related to eating, emotion, autonomic function and motor control (Table 1). Here, we only list (Table 1) but do not discuss the latter actions of orexin/hypocretin in detail, since this has
been covered extensively in recent publications (e.g. [10, 107]). We would just like to note that combined activation of arousal and reward systems may ensure that a heightened arousal accompanies reward-seeking, thereby increasing probability of reward discovery and of avoiding danger while exploring for rewards. Also, arousal and exploration may require motivational signals, since these behaviours are not intrinsically rewarding but are energy expending and potentially dangerous. Orexin/hypocretin may provide this motivation [10, 108], at least until reward consumption beings [109].

From a biophysical perspective on signal processing, the excitatory/depolarizing actions of orexin/hypocretin on central neurons (Table 1) can be divided into those increasing membrane conductance (e.g. activation of non-selective cation currents) and those decreasing it (e.g. inhibition of K⁺ currents). This has profound implications for input processing capabilities of orexin/hypocretin-modulated neurons. The ability of a current input (I) to change membrane potential (V) is inversely related to membrane conductance (g). This dependence is described by Ohm’s law, V = I/g. The neuronal firing output depends on the membrane potential (it is increased by depolarization, [110, 111]). Therefore, conductance-increasing actions of orexin/hypocretin will not only depolarize and electrically excite the target neuron but also reduce the sensitivity of the neuron’s firing to other inputs. This would effectively lock the neuron in a high-output state, which could be useful for overriding other inputs in times of danger. In turn, conductance-reducing actions of orexin/hypocretin will not only depolarize and excite the neuron but also increase its sensitivity to other inputs. This would enable the neuron to be readily modulated by other inputs (both stimulatory and inhibitory), thus allowing other inputs to either augment or cancel the orexin/hypocretin-induced excitation. Overall, these conductance-related actions of orexin/hypocretin can be viewed as not simply excitatory but also ‘gain modulating’. The ability to modulate the input-output gain is an important feature of neural computation [112]. Therefore, the functional/behavioural implications of gain-modulating postsynaptic actions of orexin/hypocretin are an important question for future investigations.

Although the direct postsynaptic actions of orexin/hypocretin are usually excitatory, there are some exceptions. Per1 neurons of the hypothalamic suprachiasmatic nucleus that function as the brain’s master circadian clock are inhibited by orexin/hypocretin via activation of leak-like K⁺ channels, as well as presynaptically by increasing GABA release [62]. Signal transduction pathways linking orexin/hypocretin receptors to the inhibitory channels remain undefined. The inhibition of mouse Per1 neurons by orexin/hypocretin may enable the circadian clock signals to be overridden by arousal need signalled by orexin/hypocretin cells.

The above summary and classification of postsynaptic actions of orexin/hypocretin highlight the diversity and some general themes of brain-wide orexin/hypocretin signalling. However, such descriptions do not reveal critical components of orexin/hypocretin actions nor why orexins/hypocretins are vital for brain function stability. To achieve the latter insights, it is necessary to understand the functionally critical modules mediating orexin/hypocretin action and the overall control system architecture implemented by these modules. We address this in the next section, continuing to focus on wakefulness control.
3 Which Orexin/Hypocretin-Regulated Sites Are Critical for Wake Stability in the Normal Brain?

The diversity of orexin/hypocretin-excited neurons throughout the brain raises the question of the relative roles of different orexin targets in preventing the narcoleptic instability of wakefulness. An optimal way to deconstruct these natural roles would be to examine the effects on wakefulness stability of targeted, specific and reversible inactivation of orexin receptors in molecularly defined neurons in adult mice. Such technically demanding experiments have not yet been accomplished. The relevant studies performed to date used other approaches, such as global receptor deletion followed by targeted receptor restoration [113, 114] or experimental stimulation of orexin/hypocretin cells concurrent with experimental silencing of specific downstream targets [25]. These approaches have caveats as far as the natural roles of orexin/hypocretin targets in wake stability are concerned. For example, given the feedback loops in wakefulness circuits (see below), the role of an orexin/hypocretin receptor site in wakefulness control when all other orexin/hypocretin sites are genetically deleted is not the same as its role in the natural brain. In turn, experimental stimulation of orexin/hypocretin cells does not reproduce their natural firing patterns, and the ability of orexin/hypocretin cells to stimulate awakening is not an assay of wakefulness stability. Nevertheless, the existing studies provide fundamental information about causal links between specific neurons and wakefulness, as well as proof-of-concept information relevant to narcolepsy treatment. Therefore, we briefly comment on some of them here (for more in-depth discussions of current literature on this topic, see [2, 115]).

Carter et al. examined the mechanism of orexin-mediated wakefulness by optogenetically stimulating orexin/hypocretin neurons while concurrently optogenetically silencing one of their downstream effectors, the orexin type 1 receptor expressing noradrenaline neurons of the locus coeruleus (LC) [25]. Note that this does not address the question of which orexin/hypocretin targets are critical for orexin/hypocretin-dependent wakefulness stability. They found that when the LC noradrenaline neurons were inactivated, stimulation of orexin/hypocretin neurons no longer produced awakening from sleep. This seminal finding establishes the noradrenaline neurons as critical generators for the orexin/hypocretin-dependent stimulation of wakefulness. However, it remains unclear how these generators are controlled in order to maintain stable wakefulness, especially since the orexin type 2 receptor (not the type 1 expressed by the LC noradrenaline neurons) is essential for the wake stability. In the next sections, we will propose a unifying framework that can reconcile the wake-generator function of the noradrenaline neurons with wake-controller functions of orexin type 2 receptor neurons.

Mochizuki et al. globally deleted orexin type 2 receptors in mice, producing a narcoleptic instability of wakefulness [113]. They then used a viral expression strategy to restore these receptors locally in the tuberomammillary hypothalamus, an area rich in histamine neurons that normally express high levels of orexin type 2 receptors. This local manipulation rescued the wakefulness instability (but interestingly, not sleep instability that also results from loss of orexin/hypocretin function). This suggests that the histamine neurons could be critical for
wake-controllers that signal to wake-generators (such as noradrenaline cells) to adjust their signals properly.

Hasegawa et al. knocked out both types of orexin/hypocretin receptors in mice and then reintroduced both of them at specific brain sites by viral delivery under a non-specific promoter. They found that such receptor overexpression in the LC restored the normal duration and number of wakefulness episodes [114]. It is not clear whether this is the normal function of the orexin signals to the locus coeruleus or an outcome of overexpression of orexin receptors that are not normally there. In contrast, the dual orexin/hypocretin receptor overexpression in the tuberomammillary hypothalamus did not restore the normal duration and number of wakefulness episodes. This shows that orexin/hypocretin signalling in the tuberomammillary hypothalamus is insufficient for normal wakefulness when all orexin receptors are missing from the locus coeruleus. Together with the data of Mochizuki et al., this can be interpreted to suggest that the tuberomammillary hypothalamus requires an orexin-sensitive downstream wakefulness generator in order to control wakefulness. For effective wakefulness control, orexin/hypocretin may need to alter the activity of both wakefulness regulators and generators in the brain, with different kinetics and via different receptors (see Fig. 3, discussed below).

4 Mapping Orexin/Hypocretin Biology onto Control Operations

The above-discussed biological measurements define functionally important components of orexin/hypocretin systems and the general signs (plus or minus) for interactions between these components. This knowledge is fundamental, but alone is insufficient to account for control operations performed by orexin/hypocretin to achieve stable wakefulness. To clarify what we mean by control operations, a brief formal definition of tracking and stability is warranted. From a general evolutionary perspective, a highly desirable attribute of arousal control is set point tracking, i.e. the ability to adjust a set point to relevant inputs while rejecting disturbances. A good tracking system will follow salient inputs while resisting disturbances. Disturbance resistance is the ability to protect a set point from irrelevant disturbance, e.g. noise in brain/body internal signals, external events not requiring arousal responses, etc. A system capable of disturbance-resistant tracking can be considered ‘robust yet flexible’. Note that this robust flexibility has to exist in the real world, i.e. where neither noise/disturbance nor important inputs are completely predictable, i.e. the control system has to be uncertainty proof. This need to deal with uncertainty imposes important requirements (and thus constraints) on system architecture (see below). For more detailed discussions of control principles as applied to orexin/hypocretin networks, see [18].

Can the actions of orexin/hypocretin be considered to implement such robust yet flexible arousal? We believe the answer is yes, since without orexin/hypocretin, arousal becomes both flexible and less robust. For example, when orexin/hypocretin is knocked out, mice cannot respond to potentially dangerous intrusions by properly increasing blood pressure [116], and they cannot properly adapt to a fall in their energy levels by increasing locomotion [8]. Thus, a vital flexibility of arousal is lost without orexin/hypocretin. In terms of robustness, it is well known that without orexin/hypocretin arousal can dip to inappropriately low levels (unconsciousness) upon disturbances such as laughter in humans.
or sight of delicious food in animals [2, 117, 118]. Without orexin/hypocretin, there is no appropriate tracking/adjustment of arousal state to internal and external state.

If orexin/hypocretin actions implement arousal tracking, the understanding of arousal control will increase by viewing orexin/hypocretin system from general perspectives of robust-yet-flexible control systems. Such systems generally must contain autocorrecting feedback loops, since neither the world nor system performance can be precisely predicted [119, 120]. As a minimum, such a feedback loop circuit must contain at least three operationally different elements in order to be robust yet flexible, which we here call a comparator, a controller and a generator (Fig. 3). This error-based feedback system is a canonical engineering strategy to track a set point despite noise [119, 120]. Note that although artificial, stimulation of each of these elements would increase the final output of the system (e.g. arousal). However, this ‘test’ does not mean that the elements are redundant: their functions and dynamics are fundamentally distinct.

These distinct functions of the three components in this autocorrecting system architecture (Fig. 3) have been discussed in detail in control engineering literature [119, 121] and recently in arousal control literature [18, 58]. A summary of the latter discussions is that orexin/hypocretin neurons display functional hallmarks of comparators, some orexin type 2 receptor neurons (histamine cells) exhibit functional signatures of controllers, while some orexin type 1 receptor neurons (noradrenaline cells) have operational features of generators (for detailed arguments, see [18]). A particularly curious feature of some orexin type 2 receptor cells is that they appear to transmit a signal resembling a temporal integral of orexin/hypocretin neuron activity (Fig. 4) [18, 58]. This integration may enable them to function as integral controllers, engineering signals that are theoretically necessary and sufficient for robust-and-flexible control mediated by orexin/hypocretin in general and its type 2 receptors in particular [18]. Therefore, from an operational perspective, integral feedback is an important candidate mechanism for how orexin/hypocretin maintains appropriate behavioural state.

5 Explanatory and Predictive Value of Viewing Orexin/Hypocretin Actions as Control Computations

What is the scientific value, for orexin/hypocretin biology and clinical applications, of control engineering theories such as those shown in Fig. 3?

First, an important corollary is that these control schemes assign a clear operational reason for the hitherto puzzling diversity of seemingly redundant wake-promoting neurons in the brain. If brain wakefulness control was operating via integral control or a related feedback scheme, there would have to be several operationally nonredundant neural types (comparators, controllers, generators) cooperating together. Note that these neurons are nonredundant in the sense of operations they perform, for example in this case, addition, integration and amplification, respectively. However, the comparator, controller and generator neurons are redundant in the sense that they all promote wakefulness if separately stimulated (this follows mathematically from the scheme in Fig. 3). The latter ‘redundancy’, however, is a by-product of experimental manipulation – it could be useful clinically for
achieving rapid arousal, but it does not mean that the wakefulness control architecture is redundant. Such considerations are attractive because they settle a long-standing enigma in the field – the diversity of wake-promoting neurons – and emphasize that wakefulness control/stability/flexibility/robustness is a separate process from wakefulness stimulation, which allows the terms redundant and nonredundant to be applied more precisely. Thus, a control view adds clarity and explanatory power to understanding how the complex biology of arousal control relates to the need for the brain to operate flexibly yet robustly in uncertain environments.

Second, control schemes such as those shown in Fig. 3 are formal mathematical theories that produce precise experimentally testable predictions about the temporal dynamics of distinct neurons. Such predictions of dynamics can be directly compared with real biological dynamics (measuring of temporal patterns of neuronal activity) and are thus essential for falsifying any theories of dynamic brain function. For example, when mathematically simulated, comparator, regulator and generator neurons produce different temporal signatures of activity in response to an input [18], and this can be experimentally tested. Furthermore, a mathematical control scheme such as that in Fig. 3 allows a proof-of-concept examination of whether a particular experimentally discovered neural operation is necessary to account for wakefulness stability. For example, if integration by orexin type 2 receptor cells is taken out of the model and replaced by a different computation (amplification), it can be mathematically demonstrated that both robustness and flexibility of the system are lost [18]. In contrast, more conventional (in biology) descriptions of arousal-implicated orexin/hypocretin biology that we gave earlier in this chapter (Fig. 1 and Table 1) are not mathematical theories and do not produce useful predictions and wakefulness dynamics. Thus, control engineering theories are useful for biology because they generate clearer predictions to guide experiments aimed at brain dynamics.

6 Overview, Omissions and Future Perspectives

In summary, we have reviewed postsynaptic orexin/hypocretin actions relating to arousal and presented a control theoretical view of these actions. This view theoretically accounts both for how orexin/hypocretin generates robust-yet-flexible arousal and for why multiple nonredundant types of arousal-promoting neurons exist in the brain.

We have omitted from this brief article many publications on the topic that have potential bearing on our interpretations. However, to the best of our knowledge, there are currently no experimental observations that invalidate our general argument. For example, under some behavioural manipulations, the actions of noradrenaline on orexin/hypocretin cells in vitro have been reported to switch from inhibition to excitation [21, 122]. However, this does not mean that under such circumstances the negative feedback of arousal signals to orexin/hypocretin neurons does not exist; for example, it can be signalled by 5-HT. It would also be important to determine whether fast transmitters expressed by arousal-promoting neurons (e.g. GABA) affect orexin/hypocretin neurons. It has also been reported that some orexin/hypocretin neurons sense orexin/hypocretin themselves via orexin type 2 receptors [123], although this is controversial [19]. This opens up the possibility that orexin/hypocretin population may perform a dual function of regulators and comparators/error generators.)
Furthermore, we did not discuss the possible reasons for why different arousal-regulating neurons synthesize and use different transmitters, considering that activating or inhibiting downstream targets could be accomplished via glutamate, GABA and their many receptors. We speculate that transmitter diversity evolved to facilitate parallel signalling in a tight space [62], but it is beyond the scope of this review to discuss this in detail.

Overall, we feel that the results of our analysis provide some evidence that control-based logic is used by orexin/hypocretin system to dynamically control arousal. Furthermore, the integral feedback model provides a framework for studying wakefulness stability in both animal models and patients with narcolepsy. This model predicts transient responses of orexin/hypocretin neurons and more sustained responses of their downstream effector neurons to a change in arousal need [58]. These specific predictions can be tested in animal models with tools such as cell type-specific neural recordings, and this testing may aid the development of biomimetic medical robotics for patients with wakefulness disabilities.

Acknowledgements
This work was funded by The Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust.

References
1. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005; 437(7063):1257–1263. [PubMed: 16251950]
2. Scammell TE. Narcolepsy. N Engl J Med. 2015; 373(27):2654–2662. [PubMed: 26716917]
3. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007; 369(9560):499–511. [PubMed: 17292770]
4. Peyron C, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000; 6(9):991–997. [PubMed: 10973318]
5. Ripley B, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001; 57(12):2253–2258. [PubMed: 11756606]
6. Nishino S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001; 50(3):381–388. [PubMed: 11558795]
7. Thannickal TC, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000; 27(3):469–474. [PubMed: 11054340]
8. Yamanaka A, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron. 2003; 38(5):701–713. [PubMed: 12797956]
9. Hara J, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001; 30(2):345–354. [PubMed: 11394998]
10. Mahler SV, et al. Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat Neurosci. 2014; 17(10):1298–1303. [PubMed: 25254979]
11. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005; 437(7058):556–559. [PubMed: 16100511]
12. Boutrel B, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A. 2005; 102(52):19168–19173. [PubMed: 16357203]
13. Sakurai T. The role of orexin in motivated behaviours. Nat Rev Neurosci. 2014; 15(11):719–731. [PubMed: 25301357]
14. Williams RH, et al. Adaptive sugar sensors in hypothalamic feeding circuits. Proc Natl Acad Sci U S A. 2008; 105(33):11975–11980. [PubMed: 18695235]
15. Williams RH, et al. Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci U S A. 2007; 104(25):10685–10690. [PubMed: 17563364]

16. Karnani MM, et al. Activation of central orexin/hypocretin neurons by dietary amino acids. Neuron. 2011; 72(4):616–629. [PubMed: 22099463]

17. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron. 2005; 46(5):787–798. [PubMed: 15924864]

18. Kosse C, Burdakov D. A unifying computational framework for stability and flexibility of arousal. Front Syst Neurosci. 2014; 8:192. [PubMed: 25368557]

19. Li Y, et al. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron. 2002; 36(6):1169–1181. [PubMed: 12495630]

20. Yamanaka A, et al. Regulation of orexin neurons by the monoaminergic and cholinergic systems. Biochem Biophys Res Commun. 2003; 303(1):120–129. [PubMed: 12646175]

21. Grivel J, et al. The wake-promoting hypocretin/orexin neurons change their response to noradrenaline after sleep deprivation. J Neurosci. 2005; 25(16):4127–4130. [PubMed: 15843615]

22. Lin L, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999; 98(3):365–376. [PubMed: 10458611]

23. Chemelli RM, et al. Narcolepsy in orexin knockout mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003; 38(5):715–730. [PubMed: 12797957]

24. Carter ME, et al. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci U S A. 2012; 109(39):E2635–E2644. [PubMed: 22955882]

25. Mieda M, et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci. 2011; 31(17):6518–6526. [PubMed: 21525292]

26. Eriksson KS, et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci. 2001; 21(23):9273–9279. [PubMed: 11717361]

27. Peyron C, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998; 18(3):9996–10015. [PubMed: 9822755]

28. Cirillo J, Caverson MM. Hypothalamic orexin-A (hypocretin-1) neuronal projections to the vestibular complex and cerebellum in the rat. Brain Res. 2014; 1579:20–34. [PubMed: 25017945]

29. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007; 8(3):171–181. [PubMed: 17299454]

30. Adamantidis AR, et al. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature. 2007; 450(7168):420–424. [PubMed: 17943086]

31. Eggermann E, et al. Orexins/hypocretins excite basal forebrain cholinergic neurons. Neuroscience. 2001; 108(2):177–181. [PubMed: 11734353]

32. Arrigoni E, Mochizuki T, Scammell TE. Activation of the basal forebrain by the orexin/hypocretin neurons. Acta Physiol (Oxf). 2010; 198(3):223–235. [PubMed: 19723027]

33. Ferrari LL, et al. Dynorphin inhibits basal forebrain cholinergic neurons by pre- and post-synaptic mechanisms. J Physiol. 2015; 594(4):1069–1085.

34. Wu M. Hypocretin/hypocretin innervation and excitation of identified septohippocampal cholinergic neurons. J Neurosci. 2004; 24(14):3527–3536. [PubMed: 15071100]

35. Mukai K, et al. Electrophysiological effects of orexin/hypocretin on nucleus accumbens shell neurons in rats: an in vitro study. Peptides. 2009; 30(8):1487–1496. [PubMed: 19416746]

36. Martin G, et al. Interaction of the hypocretins with neurotransmitters in the nucleus accumbens. Regul Pept. 2002; 104(1–3):111–117. [PubMed: 11830285]
40. Lambe EK, Aghajanian GK. Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. Neuron. 2003; 40(1):139–150. [PubMed: 14527439]

41. Lambe EK, et al. Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat. J Neurosci. 2005; 25(21):5225–5229. [PubMed: 15917462]

42. Marcus JN, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001; 435(1):6–25. [PubMed: 11370008]

43. Bayer L, et al. Exclusive postsynaptic action of hypocretin-orexin on sublayer 6b cortical neurons. J Neurosci. 2004; 24(30):6760–6764. [PubMed: 15282280]

44. Hay YA, et al. Orexin-dependent activation of layer VIb enhances cortical network activity and integration of non-specific thalamocortical inputs. Brain Struct Funct. 2015; 220:3497–3512. [PubMed: 25108310]

45. Akbari E, et al. Orexin-1 receptor mediates long-term potentiation in the dentate gyrus area of freely moving rats. Behav Brain Res. 2011; 216(1):375–380. [PubMed: 20728473]

46. Wayner MJ, et al. Orexin-A (hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides. 2004; 25(6):991–996. [PubMed: 15203246]

47. Selbach O, et al. Orexins/hypocretins control bistability of hippocampal long-term synaptic plasticity through co-activation of multiple kinases. Acta Physiol (Oxf). 2010; 198(3):277–285. [PubMed: 19624551]

48. Bayer L, et al. Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons. J Neurosci. 2002; 22(18):7835–7839. [PubMed: 12223534]

49. Lungwitz EA, et al. Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats. Physiol Behav. 2012; 107(5):726–732. [PubMed: 22652097]

50. Conrad KL, et al. Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes. Neuropsychopharmacology. 2012; 37(10):2253–2266. [PubMed: 22617356]

51. Ishibashi M, et al. Effects of orexins/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro. Peptides. 2005; 26(3):471–481. [PubMed: 15652654]

52. Huang H, Ghosh P, Pol AN. Prefrontal cortex-projecting glutamatergic thalamic paraventricular nucleus-excited by hypocretin: a feedforward circuit that may enhance cognitive arousal. J Neurophysiol. 2006; 95(3):1656–1668. [PubMed: 16492946]

53. Kolaj M, et al. Orexin-induced modulation of state-dependent intrinsic properties in thalamic paraventricular nucleus neurons attenuates action potential patterning and frequency. Neuroscience. 2007; 147(4):1066–1075. [PubMed: 17600629]

54. Palus K, Chrobok L, Lewandowski MH. Orexins/hypocretins modulate the activity of NPY-positive and -negative neurons in the rat intergeniculate leaflet via OX1 and OX2 receptors. Neuroscience. 2015; 300:370–380. [PubMed: 26022361]

55. Chrobok L, Palus K, Lewandowski MH. Orexins excite ventrolateral geniculate nucleus neurons predominantly via OX2 receptors. Neuropharmacology. 2015; 103:236–246. [PubMed: 26724374]

56. Govindaiah G, Cox CL. Modulation of thalamic neuron excitability by orexins. Neuropharmacology. 2006; 51(3):414–425. [PubMed: 16713607]

57. Yamanaka A, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun. 2002; 290(4):1237–1245. [PubMed: 11811995]

58. Schöne C, et al. Coreleased orexin and glutamate evoke nonredundant spike outputs and computations in histamine neurons. Cell Rep. 2014; 7(3):697–704. [PubMed: 24767990]

59. Hoang QV, et al. Effects of orexin (hypocretin) on GIRK channels. J Neurophysiol. 2003; 90(2):693–702. [PubMed: 12702704]

60. Eriksson KS, et al. Orexin (hypocretin/dynorphin neurons control GABAergic inputs to tuberomammillary neurons. Eur J Neurosci. 2004; 19(5):1278–1284. [PubMed: 15016085]

61. Schöne C, et al. Optogenetic probing of fast glutamatergic transmission from hypocretin/orexin to histamine neurons in situ. J Neurosci. 2012; 32(36):12437–12443. [PubMed: 22956835]
62. Belle MD, et al. Acute suppressive and long-term phase modulation actions of orexin on the mammalian circadian clock. J Neurosci. 2014; 34(10):3607–3621. [PubMed: 24599460]

63. Kohlmeier KA, Inoue T, Leonard CS. Hypocretin/orexin peptide signaling in the ascending arousal system: elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentum. J Neurophysiol. 2004; 92(1):221–235. [PubMed: 14999052]

64. Burlet S, Tyler CJ, Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: implications for wakefulness and narcolepsy. J Neurosci. 2002; 22(7): 2862–2872. [PubMed: 11923451]

65. Kim J, et al. Orexin-A and ghrelin depolarize the same pedunculopontine tegmental neurons in rats: an in vitro study. Peptides. 2009; 30(7):1328–1335. [PubMed: 19540431]

66. Horvath TL, et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol. 1999; 415(2):145–159. [PubMed: 10545156]

67. Soffin EM, et al. SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. Neuropharmacology. 2002; 42(1):127–133. [PubMed: 11750922]

68. Soffin EM, et al. Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus. Neuropharmacology. 2004; 46(8):1168–1176. [PubMed: 15111023]

69. Murai Y, Akaike T. Orexins cause depolarization via nonselective cationic and K+ channels in isolated locus coeruleus neurons. Neurosci Res. 2005; 51(1):55–65. [PubMed: 15596241]

70. Kreibich A, et al. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci. 2008; 28(25):6516–6525. [PubMed: 18562623]

71. Henny P, et al. Immunohistochemical evidence for synaptic release of glutamate from orexin terminals in the locus coeruleus. Neuroscience. 2010; 169(3):1150–1157. [PubMed: 20540992]

72. Brown RE, et al. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci. 2002; 22(20):8850–8859. [PubMed: 12388591]

73. Liu RJ, Pol AN, Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci. 2002; 22(21):9453–9464. [PubMed: 12417670]

74. Haj-Dahmane S, Shen RY. The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J Neurosci. 2005; 25(4):896–905. [PubMed: 15673670]

75. Bisetti A, et al. Excitatory action of hypocretin/orexin on neurons of the central medial amygdala. Neuroscience. 2006; 142(4):999–1004. [PubMed: 16996221]

76. Pol AN, et al. Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. Neuron. 2004; 42(4):635–652. [PubMed: 15157424]

77. Li Y, Pol AN. Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. J Neurosci. 2006; 26(50):13037–13047. [PubMed: 17167093]

78. Burdakov D, Liss B, Ashcroft FM. Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium–calcium exchanger. J Neurosci. 2003; 23(12):4951–4957. [PubMed: 12832517]

79. Muroya S, et al. Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca 2+ signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. Eur J Neurosci. 2004; 19(6):1524–1534. [PubMed: 15066149]

80. Top M, et al. Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus. Nat Neurosci. 2004; 7(5):493–494. [PubMed: 15097991]

81. Ma X, et al. Electrical inhibition of identified anorexigenic POMC neurons by orexin/hypocretin. J Neurosci. 2007; 27(7):1529–1533. [PubMed: 17301161]

82. Shirasaka T, et al. Orexin depolarizes rat hypothalamic paraventricular nucleus neurons. Am J Physiol Regul Integr Comp Physiol. 2001; 281(4):R1114–R1118. [PubMed: 11557617]
83. Muschamp JW, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A. 2014; 111(16):E1648–E1655. [PubMed: 24706819]

84. Uramura K, et al. Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport. 2001; 12(9):1885–1889. [PubMed: 11435917]

85. Borgland SL, Storm E, Bonci A. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. Eur J Neurosci. 2008; 28(8):1545–1556. [PubMed: 18793323]

86. Korotkova TM, et al. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci. 2003; 23(1):7–11. [PubMed: 12514194]

87. Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Front Neurosci. 2014; 8:22–22. [PubMed: 24574958]

88. Kohlmeier KA, et al. Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels. J Neurophysiol. 2008; 100(4):2265–2281. [PubMed: 18667550]

89. Dias MB, Li A, Nattie EE. Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J Physiol. 2009; 587(Pt 9):2059–2067. [PubMed: 19273574]

90. Shahid IZ, Rahman AA, Pilowsky PM. Orexin and central regulation of cardiorespiratory system. Vitam Horm. 2012; 89:159–184. [PubMed: 22640613]

91. Lazarenko RM, et al. Orexin A activates retrotrapezoid neurons in mice. Respir Physiol Neurobiol. 2011; 175(2):283–287. [PubMed: 21145990]

92. Young JK, et al. Orexin stimulates breathing via medullary and spinal pathways. J Appl Physiol (1985). 2005; 98(4):1387–1395. [PubMed: 15557013]

93. Smith BN, et al. Selective enhancement of excitatory synaptic activity in the rat nucleus tractus solitarius by hypocretin 2. Neuroscience. 2002; 115(3):707–714. [PubMed: 12435409]

94. Yang B, Ferguson AV. Orexin-A depolarizes nucleus tractus solitarius neurons through effects on nonselective cationic and K+ conductances. J Neurophysiol. 2003; 89(4):2167–2175. [PubMed: 12611968]

95. Azhdari-Zarmehri H, Semnanian S, Fathollahi Y. Orexin-a modulates firing of rat rostral ventromedial medulla neurons: an in vitro study. Cell J. 2015; 17(1):163–170. [PubMed: 25870847]

96. Huang SC, et al. Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors. J Pharmacol Exp Ther. 2010; 334(2):522–529. [PubMed: 20494957]

97. Antunes VR, et al. Orexins/hypocretins excite rat sympathetic preganglionic neurons in vivo and in vitro. Am J Physiol Regul Integr Comp Physiol. 2001; 281(6):R1801–R1807. [PubMed: 11705764]

98. Top M, et al. Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones. J Physiol. 2003; 549(3):809–821. [PubMed: 12702746]

99. Zhang GH, et al. Orexin A activates hypoglossal motoneurons and enhances genioglossus muscle activity in rats. Br J Pharmacol. 2014; 171(18):4233–4246. [PubMed: 24846570]

100. Corcoran A, Richerson G, Harris M. Modulation of respiratory activity by hypocretin-1 (orexin A) in situ and in vitro. Adv Exp Med Biol. 2010; 669:109–113. [PubMed: 20217331]

101. Ivanov A, Aston-Jones G. Hypocretin/orexin depolarizes and decreases potassium conductance in locus coeruleus neurons. Neuroreport. 2000; 11(8):1755–1758. [PubMed: 10852238]

102. Peever JH, Lai Y-Y, Siegel JM. Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J Neurophysiol. 2003; 89(5):2591–2600. [PubMed: 12611960]

103. Yu L, et al. Orexin excites rat inferior vestibular nuclear neurons via co-activation of OX1 and OX2 receptors. J Neural Transm (Vienna). 2015; 122(6):747–755. [PubMed: 25371350]

104. Korotkova TM, et al. Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro. Regul Pept. 2002; 104(1–3):83–89. [PubMed: 11830281]
105. Yu L, et al. Orexins excite neurons of the rat cerebellar nucleus interpositus via orexin 2 receptors in vitro. Cerebellum. 2010; 9(1):88–95. [PubMed: 19921532]

106. Dergacheva O, et al. Orexinergic modulation of GABAergic neurotransmission to cardiac vagal neurons in the brain stem nucleus ambiguous changes during development. Neuroscience. 2012; 209:12–20. [PubMed: 22390944]

107. Lecca L, et al. Addiction and arousal: alternative roles of hypothalamic peptides. J Neurosci. 2006; 26(41):10372–10375. [PubMed: 17035520]

108. Patyal R, Woo EY, Borgland SL. Local hypocretin-1 modulates terminal dopamine concentration in the nucleus accumbens shell. Front Behav Neurosci. 2012; 6:82. [PubMed: 23226119]

109. Gonzalez JA, et al. Inhibitory interplay between orexin neurons and eating. Curr Biol. 2016; 26(18):2486–2491. [PubMed: 27546579]

110. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952; 117(4):500–544. [PubMed: 12991237]

111. Koch, C. Biophysics of computation. Oxford University Press; New York: 1999.

112. Salinas E, Thier P. Gain modulation: a major computational principle of the central nervous system. Neuron. 2000; 27(1):15–21. [PubMed: 10939327]

113. Mochizuki T, et al. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci U S A. 2011; 108(11):4471–4476. [PubMed: 21368172]

114. Hasegawa E, et al. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest. 2014; 124(2):604–616. [PubMed: 23482351]

115. Sakurai T. Orexin deficiency and narcolepsy. Curr Opin Neurobiol. 2013; 23(5):760–766. [PubMed: 23663890]

116. Kayaba Y, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol. 2003; 285(3):R581–R593. [PubMed: 12750151]

117. Meletti S, et al. The brain correlates of laugh and cataplexy in childhood narcolepsy. J Neurosci. 2015; 35(33):11583–11594. [PubMed: 26290235]

118. Burgess CR, et al. Amygdala lesions reduce cataplexy in orexin knock-out mice. J Neurosci. 2013; 33(23):9734–9742. [PubMed: 23739970]

119. DiStefano, J., Stubberud, A., Williams, I. Feedback and control systems. 2nd ed. McGraw-Hill; 2012.

120. Csete ME, Doyle JC. Reverse engineering of biological complexity. Science. 2002; 295:1664–1669. [PubMed: 11872830]

121. Aström K, Hagglund T. PID controllers: theory, design, and tuning. Instrument Society of America (ISA). 1995 ISBN-10: 1556175167.

122. Uschakov A, et al. Sleep-deprivation regulates alpha-2 adrenergic responses of rat hypocretin/orexin neurons. PLoS One. 2011; 6(2):e16672. [PubMed: 21347440]

123. Yamanaka A, et al. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010; 30(38):12642–12652. [PubMed: 20861370]

124. Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol. 2008; 29(1):70–87. [PubMed: 17910982]

125. Lu J, et al. A putative flip-flop switch for control of REM sleep. Nature. 2006; 441(7093):589–594. [PubMed: 16681848]

126. Sakurai T, et al. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron. 2005; 46(2):297–308. [PubMed: 15848807]

127. Yoshida K, et al. Afferents to the orexin neurons of the rat brain. J Comp Neurol. 2006; 494(5):845–861. [PubMed: 16374809]

128. Tsujino N, et al. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. J Neurosci. 2005; 25(32):7459–7469. [PubMed: 16093397]

129. Gonzalez JA, et al. Awake dynamics and brain-wide direct inputs of hypothalamic MCH and orexin networks. Nat Commun. 2016; 7:11395. [PubMed: 27102565]

130. Schöne C, Burdakov D. Glutamate and GABA as rapid effectors of hypothalamic “peptidergic” neurons. Front Behav Neurosci. 2012; 6:81. [PubMed: 23189047]
Input and outputs of orexin/hypocretin cells. Orexin/hypocretin neurons are activated during high vigilance states associated with high gamma EEG, requiring increased arousal such as exploratory behaviour or upon sensory or emotional stimulation. A multitude of excitatory and inhibitory substances modulates orexin/hypocretin cell activity. These include hormones, neuropeptides and small molecule transmitters as well as homeostatic signals. Orexin/hypocretin neurons receive direct inputs from brain areas involved in sleep/wake control, appetite control and reward. Orexin/hypocretin neurons integrate this information...
via the release of orexin peptides, affecting postsynaptic gain and synaptic drive in target neurons. Orexin/hypocretin activity may thereby gate relevant information based on environmental and homeostatic needs [14, 16, 124–129]
Fig. 2.
Main anatomical targets for orexin/hypocretin control of cortical arousal, appetite, emotional arousal and physical arousal. Together, orexin/hypocretin control of these targets would facilitate exploratory or escape behaviour.
Fig. 3.
Brain arousal systems as control modules in a feedback loop. (a) A generalized control system architecture (integral feedback loop) for tracking a desired set point (D) despite unpredictable disturbances. After [120]. (b) Possible implementation of A by a diversity of wake-promoting neurons in the brain (from more detail, see [18]).
Fig. 4. Orexin/hypocretin and glutamate co-transmission enables fast and sustained control of histamine neurons. (a) Targeted expression of light-sensitive ion channel ChR2 enables selective control of excitatory membrane currents in orexin/hypocretin cells. (b) Cre-dependent expression of virally delivered ChR2-eYFP in orexin-cre mice allows selective expression in lateral hypothalamic orexin-positive neurons. Data are from [61]. (c) Left: Light-activated action potential firing in ChR2-eYFP-expressing orexin/hypocretin cells recorded using whole-cell patch clamp. Right: Whole-cell recording of histamine neurons.
shows increased glutamate inputs (bottom) and action potential firing (top) upon light stimulation of adjacent orexin/hypocretin fibres. Adapted from [130], Fig. 2. (d) Top: Prolonged stimulation of orexin/hypocretin fibres for 30 s at 20 Hz produces fast and sustained increase in histamine cell firing. Bottom: Blockade of CNQX-sensitive glutamate currents blocks the fast rise in histamine firing, while a slow, long-lasting component remains. In contrary, orexin 2 receptor blockade (TCS) abolishes the slow component, leaving the fast component unaltered. Data from [58]. (e) Orexin-mediated increase in histamine firing integrates orexin/hypocretin activity (top), while glutamate-mediated increase in histamine firing does not (bottom). Data from [58]
## Postsynaptic effects of orexin/hypocretin neurons on sleep-/wakefulness-/arousal-related targets

| Brain area | Nucleus | Targets | Receptor/ligand | Mechanism of action | References |
|------------|---------|---------|----------------|---------------------|------------|
| Cerebral cortex | PFC | OR1/orexin | Excitation: presynaptic excitation of boutons from excitatory thalamocortical projecting neurons in layer V | [40–42] |
| | Visual cortex | Layer 6b pyramidal | OR2/orexin | Excitation: TTX insensitive | [43] |
| | Other layers | | | Increase synaptic inputs, improved spike timing of layer VIa responses to thalamic nucleus | [43–44] |
| | Hippocampus | DG | OR1/orexin | OR1 mediates induction of LTP in dentate gyrus of freely moving rats, Orexin A enhances LTP in dentate gyrus of urethane anesthetized rats | [45–46] |
| | | CA1 | OR1/orexin A | Orexin A but not B induced LTP in Schaffer collateral – CA1 synapses in adult, while it induced LTD in juvenile mouse hippocampal sections | [47] |
| Cerebral nuclei | SI, MPO | Cholinergic neurons | OR2/orexin | Excitation: inhibition of constitutively active inward rectifier K+ current, potentiation of evoked EPSCs | [32–34] |
| | | k-opioid/Dyn | Inhibition: activation of inward rectifier potassium current, inhibition of voltage sensitive calcium current, presynaptic depression of glutamatergic inputs | [35] |
| | Medial septum, DBB | Septo-hippocampal cholinergic | OR2/orexin | Excitation: two ionic mechanisms with 80% overlap: inhibition of an inwardly rectifying K+ conductance and activation of an Na+/Ca2+ exchanger; Inhibition: increased GABA release (spike dependent, via activation of interneuron) | [36, 37] |
| | | Septo-hippocampal GABAergic | OR2/orexin | Excitation, activation of sodium–calcium exchanger; Inhibition by increasing local, spike dependent GABA release | [37] |
| | NA | Accumbens shell | OR2/orexin | Excitation: increase of nonselective cationic conductance and decrease of K+ conductance; Inhibition: decrease of NMDA currents and increased GABA currents in dissociated cells | [38, 39] |
| | BNST | OR1/orexins | Excitation: subset of neurons; Inhibition: OR1 dependent depression of excitatory transmission | [40, 50] |
| Thalamus | MTN | OR2/orexin | Excitation: closure of potassium channels and activation of nonselective cation channels | [48, 51–53] |
| | IGL | NPY+ and – neurons | OR1/2/orexin | Excitation (58% of neurons): direct; Inhibition: increased inhibitory synaptic inputs | [54] |
| | VGN | NO+ and – neurons | OR1/2/orexin | Excitation | [55] |
| | CLN, PFN, MDT, TRN | OR1/2/orexin | Excitation of subset of neurons: inhibition of K+ current | [56] |
| | LP, LD, LGN | | No effect | [56] |
| Hypothalamus | TMN | Histamine | OR2/orexin | Excitation: activation of sodium–calcium exchanger, inhibition of G-protein coupled inward rectifier channel in cell culture; Excitation: presynaptic increase GABA inputs | [27, 57, 59, 60, 61] |
| | POA | GABAergic | Orexin | No effect | [32] |
| | SCN | OR1/2/orexins | Excitation | [62] |
| Brain area | Nucleus | Targets | Receptor/ligand | Mechanism of action | References |
|------------|---------|---------|----------------|---------------------|------------|
| LHA        | MCH     | OR2/orexin | Excitation: direct inward current, inhibition of K+ current, increase excitatory synaptic inputs. Inhibition: activate inhibitory GABA-mediated synaptic currents. | [76] |
|            |        | Orexin  | Excitation: increase of excitatory synaptic inputs. | [73] |
| Arc        | GABA neurons | OR2/orexin | Excitation: activation of sodium-calcium-exchanger. | [78] |
|            | NPV/AGRP neurons | OR1/2/orexin | Excitation: activation of inward current, phospholipase C dependent increase in intracellular calcium. | [79, 77, 80] |
|            | POMC neurons | OR2/orexin | Inhibition: decrease intracellular calcium, increase of inhibitory synaptic tone, decrease excitatory synaptic tone. | [42, 79, 81] |
| PVN        | Type 1 and type 2 neurons | OR2/orexin B | Excitation: 50–80% of neurons. | [82] |
| Cerebellum |        |        | Excitation: decrease of potassium current, increase of nonselective cationic current. | [85] |
| Midbrain   | PPT     | OR1/orexin | Excitation: 50–80% of neurons. | [82] |
|            | DR      | OR2/orexin | Excitation: activation of sodium-potassium nonselective cation channels, protein kinase C dependent enhancement of Ca2+ transients mediated by L-type Ca2+ channels. | [63, 68, 72, 73, 88] |
|            | GABA neurons | OR1/2/orexin | Excitation: increase of intracellular calcium via phosphatidylinositol-specific phospholipase C- and protein kinase C- signalling pathways to activate of L- and N-type Ca2+ channels. | [42, 73] |
|            | VTA     | OR1/2/orexin | Excitation: protein kinase C dependent postsynaptic potentiation of NMDA receptors. Inhibition: reduction of spike-timing induced LTP. | [85] |
|            | Non-dopamine neurons | Orexin | Excitation. | [86] |
|            | RMR     | OR1/orexin | Excitation: protein kinase A dependent. | [804] |
|            | SN-Pars reticulata | GABAAergic | Excitation: protein kinase A dependent. | [804] |
|            | SN-Pars compacta | Dopaminergic | Excitation. | [804] |
| Basal ganglia | LDT | Cholinergic neurons | OR1/orexin | Excitation: activation of noisy cation channels, activation of protein kinase C (PKC)-dependent enhancement of Ca2+ transients mediated by L-type Ca2+ channels, enhanced spontaneous EPSCs. | [26, 64, 88] |
|            | LC      | Noradrenergic | OR1/orexin | Excitation: depolarization and reduction in the slow component of the afterhyperpolarization (AHP). | [66] |
|            | LC cells | OR1/orexin | Excitation: augmentation of nonselective cation conductance, inhibition of sustained potassium conductance, inhibition of G-protein coupled inward rectifier channel in cell culture. | [59, 67-69, 101] |
|            | TGNM    | Motor neurons | OR1/orexin | Excitation: NMDA dependent excitation. | [42, 102] |
| Medulla    | AeTN    | Acid sensing neurons | OR1/orexin | Excitation. | [80-91] |
|            | Pre-Bötz | OR1/2/orexin | Increase in diaphragm electromyographic activity. | [90, 92] |
| Brain area | Nucleus | Targets | Receptor/ligand | Mechanism of action | References |
|------------|---------|---------|----------------|--------------------|------------|
| NAc | Cardiac vagal neurons | OR1/2/orexins | Excitation: 90% of NTS cells through inhibition of sustained K⁺ current, activation of nonselective cationic conductance; hypocretin 2 increased mEPSCs in dorsal NTS neurons | [42, 93, 94] |
| NAm | Cardiac vagal neurons | OR2/orexins | In postnatal day 5 rats: inhibition: enhanced GABAergic postsynaptic currents In postnatal day 20 and 30 rats: excitation: inhibition of GABAergic postsynaptic currents | [42, 106] |
| RVMM | OR1/orexin A | Excitation: majority of neurons, possible indirect mechanisms; Inhibition: subset of neurons with irregular firing pattern that lack fast afterhyperpolarization | Possible indirect action | [95] |
| RVLM | OR1-2/orexin A | Excitation: subset of neurons | | [90, 96] |
| LVN | OR1/2/orexins | Excitation: activation of sodium-calcium exchanger, block of inward rectifier K⁺ current | | [99] |
| IVN | OR1/2/orexins | Direct excitation | | [103] |
| Spinal cord | Sympathetic preganglionic neurons | OR1/2/orexins | Excitation, inhibition of potassium conductance via protein kinase A-dependent pathway | | [97, 98] |
| | Phrenic/hypoglossal motor neurons | OR1/2/orexins | Direct excitation in 1 μM tetrodotoxin | | [89, 90, 99, 100] |

Abbreviations: Ac, arcuate nucleus; BNST, bed nucleus stria terminalis; Ce, central medial amygdala; CIN, cerebellar interpositus nucleus; CLN, centrolateral nucleus of the thalamus; DHR, diagonal band of broca; DR, dorsal raphe; DLS, dorsal lateral striatum; Dyn, dynorphin; Glu, glutamate; IGL, intergeniculate leaflet; IPN, intrapeptidergic nucleus; LC, locus ceruleus; LDT, laterodorsal tegmental nucleus; LGN, lateral geniculate nucleus; LHA, lateral hypothalamic area; LP, lateral posterior geniculate nucleus; LD, laterodorsal geniculate nucleus; LVN, lateral ventral nucleus; MD, mediodorsal; MPO, magnocellular preoptic nucleus; MTN, midline thalamic nuclei; NAc, nucleus accumbens; NTS, nucleus tractus solitarius; OR1/2, orexin receptor 1/2; P, posterior; PVN, paraventricular nucleus of the hypothalamus; ReTr, retro trapezoid nucleus; RVL, rostral ventrolateral medulla; RVMM, rostral ventro-medial medulla; RMr, rostral medullary raphe; SCN, suprachiasmatic nucleus; SN, substantia nigra; TMG, trigeminal motor nucleus; VMH, ventromedial hypothalamus; VTA, ventral tegmental area.